Skip to Content

Zai Lab Ltd ADR Repr 1 Shs ZLAB

Morningstar Rating
$16.32 +0.15 (0.93%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

ZLAB is trading at a 41% discount.
Price
$16.15
Fair Value
$37.52
Uncertainty
Extreme
1-Star Price
$88.59
5-Star Price
$3.84
Economic Moat
Jkv
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ZLAB is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$16.17
Day Range
$16.2316.36
52-Week Range
$15.6940.17
Bid/Ask
$16.22 / $16.32
Market Cap
$1.62 Bil
Volume/Avg
11,696 / 663,935

Key Statistics

Price/Earnings (Normalized)
Price/Sales
5.87
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Mid Core
Total Number of Employees
2,175

Comparables

Valuation

Metric
ZLAB
APLM
02105
Price/Earnings (Normalized)
Price/Book Value
1.980.972.38
Price/Sales
5.87
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
ZLAB
APLM
02105
Quick Ratio
4.293.769.91
Current Ratio
4.633.929.98
Interest Coverage
−3,564.95−447.63
Quick Ratio
ZLAB
APLM
02105

Profitability

Metric
ZLAB
APLM
02105
Return on Assets (Normalized)
−22.36%−342.84%−48.47%
Return on Equity (Normalized)
−26.78%
Return on Invested Capital (Normalized)
−30.45%
Return on Assets
ZLAB
APLM
02105
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRVzqtfygkqzNxnx$571.0 Bil
VRTX
Vertex Pharmaceuticals IncGhnwcgfpvRydbr$107.8 Bil
REGN
Regeneron Pharmaceuticals IncWrprpkqrGztbqz$106.1 Bil
MRNA
Moderna IncJypygjbmTptk$42.3 Bil
ARGX
argenx SE ADRGyxvdzdpZzg$23.7 Bil
BNTX
BioNTech SE ADRTmqcbrvxrKlltd$22.1 Bil
ALNY
Alnylam Pharmaceuticals IncRrcbshmzQmrwyvq$19.4 Bil
BMRN
Biomarin Pharmaceutical IncCsnqhldhDljpzp$16.7 Bil
RPRX
Royalty Pharma PLC Class AZvsjfvbpSnqbrs$13.6 Bil
INCY
Incyte CorpDhbsvmhtQtcbptj$12.8 Bil

Sponsor Center